Opening soon. Stay in the loop

goodmorrowJoin the opening list

Thymosin alpha-1, explained.

Thymalfasin (Zadaxin). Research, safety questions, and treatment context.

Updated Clinical review pending · Educational draft

The form

Pharmacy catalog form

The routine

Schedules in hospital studies are not everyday wellness instructions.

The evidence

Human illness studies · everyday benefit uncertain

Forms listed in a June 2025 catalog. Current availability and individual instructions need confirmation.

Legal status
No lawful route today

No lawful compounding route in the U.S. today. Approved as a drug in several other countries.

At Goodmorrow
Not offered

What it is

Thymosin alpha-1 is a 28-amino-acid peptide made by the thymus, the gland that trains immune cells.

What the evidence shows

It has been studied in people for decades, mostly for hepatitis B and C and as an add-on in cancer care and severe infection. The results are mixed, but they exist, which puts it ahead of most peptides sold for wellness.

How Goodmorrow handles it

Not offered today. We'll revisit it if the FDA puts it back on the compounding list.

Questions people ask

Will thymosin alpha-1 come back?

Federal health officials named it in early 2026 as a candidate to return, but it wasn't part of the July 2026 review. There's no date.

Sources

  1. Secondary sourceThe Peptide Reclassification Everyone's Talking About: A Pharmacist's Take Pharmacy Times, 2026
  2. Secondary sourceThe US Peptide Status Index Peptide America

Good days ahead.

Join the opening list for appointment updates.

Join the opening list